| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the … R Stupp, ME Hegi, WP Mason, MJ Van Den Bent, MJB Taphoorn, ... The lancet oncology 10 (5), 459-466, 2009 | 8035 | 2009 |
| Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas M Sanson, Y Marie, S Paris, A Idbaih, J Laffaire, F Ducray, S El Hallani, ... J Clin Oncol 27 (25), 4150-4154, 2009 | 1171 | 2009 |
| European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of … R Stupp, ME Hegi, WP Mason, MJ van den Bent, MJ Taphoorn, ... Lancet Oncol 10 (5), 459-466, 2009 | 1004 | 2009 |
| Radiotherapy for glioblastoma in the elderly F Keime-Guibert, O Chinot, L Taillandier, S Cartalat-Carel, M Frenay, ... New england journal of medicine 356 (15), 1527-1535, 2007 | 934 | 2007 |
| High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses J Haroche, F Charlotte, L Arnaud, A Von Deimling, Z Hélias-Rodzewicz, ... Blood, The Journal of the American Society of Hematology 120 (13), 2700-2703, 2012 | 676 | 2012 |
| IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas C Houillier, X Wang, G Kaloshi, K Mokhtari, R Guillevin, J Laffaire, S Paris, ... Neurology 75 (17), 1560-1566, 2010 | 580 | 2010 |
| Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy C Besson, A Goubar, J Gabarre, W Rozenbaum, G Pialoux, FP Châtelet, ... Blood, The Journal of the American Society of Hematology 98 (8), 2339-2344, 2001 | 463 | 2001 |
| Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 445 | 2020 |
| A uniform activated B-cell–like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases S Camilleri-Broët, E Criniere, P Broët, V Delwail, K Mokhtari, A Moreau, ... Blood 107 (1), 190-196, 2006 | 430 | 2006 |
| A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry S El Hallani, B Boisselier, F Peglion, A Rousseau, C Colin, A Idbaih, ... Brain 133 (4), 973-982, 2010 | 420 | 2010 |
| Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions K Hoang-Xuan, L Capelle, M Kujas, S Taillibert, H Duffau, J Lejeune, ... Journal of clinical oncology 22 (15), 3133-3138, 2004 | 411 | 2004 |
| A phase I/II study of herpes simplex virus type 1 thymidine kinase “suicide” gene therapy for recurrent glioblastoma D Klatzmann, CA Valery, G Bensimon, B Marro, O Boyer, K Mokhtari, ... Human gene therapy 9 (17), 2595-2604, 1998 | 356 | 1998 |
| Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome G Kaloshi, A Benouaich-Amiel, F Diakite, S Taillibert, J Lejeune, ... Neurology 68 (21), 1831-1836, 2007 | 343 | 2007 |
| All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 M Labussiere, A Idbaih, XW Wang, Y Marie, B Boisselier, C Falet, S Paris, ... Neurology 74 (23), 1886-1890, 2010 | 319 | 2010 |
| Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis P Metellus, B Coulibaly, C Colin, AM de Paula, A Vasiljevic, D Taieb, ... Acta neuropathologica 120, 719-729, 2010 | 316 | 2010 |
| Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors BS Melin, JS Barnholtz-Sloan, MR Wrensch, C Johansen, D Il'Yasova, ... Nature genetics 49 (5), 789-794, 2017 | 314 | 2017 |
| Pitfalls in the diagnosis of brain tumours AMP Omuro, CC Leite, K Mokhtari, JY Delattre The Lancet Neurology 5 (11), 937-948, 2006 | 266 | 2006 |
| Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas A Gonzalez-Aguilar, A Idbaih, B Boisselier, N Habbita, M Rossetto, ... Clinical cancer research 18 (19), 5203-5211, 2012 | 260 | 2012 |
| MGMT methylation: a marker of response to temozolomide in low‐grade gliomas S Everhard, G Kaloshi, E Crinière, A Benouaich‐Amiel, J Lejeune, ... Annals of Neurology: Official Journal of the American Neurological …, 2006 | 252 | 2006 |
| Detection, characterization, and inhibition of FGFR–TACC fusions in IDH wild-type glioma AL Di Stefano, A Fucci, V Frattini, M Labussiere, K Mokhtari, P Zoppoli, ... Clinical cancer research 21 (14), 3307-3317, 2015 | 249 | 2015 |
